Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644595 | 1.00 | KMT2A (0.49) | KMT2AACEGPR139MMEALDH1A1 | |
| SCHEMBL7898278 | 1.00 | KMT2A (0.49) | KMT2AACEGPR139MMEALDH1A1 | |
| SCHEMBL5695631 | 0.86 | GPR139 (0.50) | KMT2AACEGPR139MMEALDH1A1 | |
| SCHEMBL7897731 | 0.86 | GPR139 (0.50) | KMT2AACEGPR139MMEALDH1A1 | |
| SCHEMBL1356206 | 0.86 | GPR139 (0.50) | KMT2AACEGPR139MMEALDH1A1 | |
| SCHEMBL11449617 | 0.85 | GSK3B (0.42) | KMT2AACEALDH1A1LMNAHPGD | |
| Hydrochloric Acid SCHEMBL643490 | 0.84 | GPR139 (0.49) | KMT2AACEGPR139MMEALDH1A1 | |
| Hydrochloric Acid SCHEMBL7450354 | 0.84 | GPR139 (0.49) | KMT2AACEGPR139MMEALDH1A1 | |
| SCHEMBL6057191 | 0.82 | GPR139 (0.53) | KMT2AACEGPR139MMEALDH1A1 | |
| SCHEMBL7342775 | 0.81 | HDAC3 (0.46) | ALDH1A1MAPTLMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101012192-A | Method of preparing zofenopril calcium | GUANGDONG BANGMIN PHARMACEUTIC (CN) | 2007-08-08 | — | — | CN | claimed |
| EP-1102745-B1 | A PROCESS FOR THE PREPARATION OF ZOFENOPRIL CALCIUM SALT | MENARINI INT OPERATIONS LU SA (LU) | 2004-05-12 | — | — | EP | claimed |
| US-6521760-B1 | Process for the preparation of zofenopril calcium salt | MENARINI RICHERCHE S.P.A. (IT) | 2003-02-18 | — | — | US | claimed |
| EP-2245007-B1 | Process for preparing a crystalline form of zofenopril calcium | GENERICS UK LTD (GB) | 2020-08-19 | — | — | EP | disclosed |
| US-9221754-B2 | Crystalline forms of zofenopril calcium | GENERICS [UK] LIMITED (GB) | 2015-12-29 | — | — | US | disclosed |
| EP-1899297-B1 | ZOFENOPRIL CALCIUM IN POLYMORPH FORM C | GENERICS UK LTD (GB) | 2015-12-09 | — | — | EP | disclosed |
| EP-2173710-B1 | NOVEL CRYSTALLINE FORM | GENERICS UK LTD (GB) | 2015-09-16 | — | — | EP | disclosed |
| US-20140378523-A1 | NOVEL CRYSTALLINE FORMS OF ZOFENOPRIL CALCIUM | TIANISH LABORATORIES PRIVATE LIMITED (IN) | 2014-12-25 | — | — | US | disclosed |
| EP-2041083-B1 | METHODS OF PREPARING ZOFENOPRIL CALCIUM | GENERICS UK LTD (GB) | 2014-11-05 | — | — | EP | disclosed |
| US-8853421-B2 | Crystalline forms of zofenopril calcium | GENERICS [UK] LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-20140163241-A1 | NOVEL CRYSTALLINE FORMS | GENERICS [UK] LIMITED (GB) | 2014-06-12 | — | — | US | disclosed |
| US-4457935-A | ANGIOTENSIN-CONVERTING ENZYME INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1984-07-03 | — | — | US | disclosed |
| US-4430344-A | Antihypertensive 4-thiazolidinecarboxylic acids | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1984-02-07 | — | — | US | disclosed |
| US-4423054-A | Antihypertensive 4-thiazolidinecarboxylic acids (substituted alkyl derivatives) | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1983-12-27 | — | — | US | disclosed |
| US-4386096-A | ANGIOTENSIN-CONVERTING ENZYME INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1983-05-31 | — | — | US | disclosed |
| US-4380644-A | HYPOTENSIVE AGENTS | TANABE SIYAKU CO., LTD. (JP) | 1983-04-19 | — | — | US | disclosed |
| US-4356183-A | ENZYME INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1982-10-26 | — | — | US | disclosed |
| EP-0052696-A1 | Novel 2-oxoimidazolidine derivative, a process for preparing same and a pharmaceutical composition containing the 2-oxoimidazolidine derivative | Tanabe Seiyaku Co., Ltd. (JP) | 1982-06-02 | — | — | EP | disclosed |
| EP-0035868-A1 | Bicyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-09-16 | — | — | EP | disclosed |
| US-4264620-A | HYPOTENSIVE AGENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1981-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163241-A1 | NOVEL CRYSTALLINE FORMS | REN, CA2, ACE | KMT2A 3701/4885ACE 3/4885GPR139 2805/4885 |
| US-20140378523-A1 | NOVEL CRYSTALLINE FORMS OF ZOFENOPRIL CALCIUM | REN, ACE, CA2 | KMT2A 3807/4885ACE 2/4885GPR139 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.